Clinical Trials Using Sipuleucel-T

Clinical trials are research studies that involve people. The clinical trials on this list are studying Sipuleucel-T. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-3 of 3
  • Sipuleucel-T with or without Low-Protein Diet in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This randomized pilot phase II trial studies how well sipuleucel-T with or without low-protein diet works in treating patients with castration-resistant prostate cancer that has spread to other parts of the body. Vaccines made from a person's white blood cells mixed with tumor proteins may help the body build an effective immune response to kill tumor cells. Giving a low-protein diet may help sipuleucel-T work better than it does when giving with a standard protein-diet in treating patients with prostate cancer.
    Location: Indiana University / Melvin and Bren Simon Cancer Center, Indianapolis, Indiana

  • Atezolizumab and Sipuleucel-T in Treating Patients with Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

    This randomized phase Ib trial study will assess the sequence of the administration of atezolizumab and sipuleucel-T and to see how well they work in treating patients with castration resistant metastatic prostate cancer without symptoms or with minimal symptoms. Atezolizumab may enhance the body's ability to recognize abnormal, tumor cells. Vaccines, such as sipuleucel-T, made from a person’s white blood cells mixed with tumor proteins may help the body build an effective immune response to kill prostate tumor cells. Giving atezolizumab and sipuleucel-T may work better in treating patients with castration resistant metastatic prostate cancer.
    Location: University of Hawaii at Manoa, Honolulu, Hawaii

  • Sipuleucel-T and Stereotactic Ablative Body Radiation Therapy in Treating Patients with Metastatic Castration-Resistant Prostate Cancer

    This phase II trial studies how well sipuleucel-T and stereotactic body radiation therapy (stereotactic ablative body radiation therapy) work in treating patients with prostate cancer that does not respond to hormone therapy that has spread to other places in the body (metastatic). Vaccines made from a person’s white blood cells mixed with tumor proteins may help the body build an effective immune response to kill prostate cancer cells. Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving sipuleucel-T with stereotactic ablative body radiation therapy may kill more tumor cells.
    Location: UT Southwestern / Simmons Cancer Center-Dallas, Dallas, Texas